The groundbreaking success of the copyright undeniably transformed the drug landscape, but placing funds in companies strongly reliant on unbranded versions presents a challenging picture. Although early profits were significant, the expiration of patents and the appearance of less expensive alternatives have diminished sales. Thus, a thorough eval